1. India Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited

ADVENZYMES.BO
Advanced Enzyme Technologies LimitedIN flagBombay Stock Exchange
320.00
INR
-0.90
- -
35.82BMarket Cap
Advanced Enzyme Technologies Limited
ADVENZYMES.BO
(Bombay Stock Exchange)

Recent

price

320.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
11.2
16.52
20.6
19.71
20.41
26.89
29.69
34.75
37.42
39.54
44.8
47.32
48.33
55.76
56.93
66.66
66.66
Revenue per Share
1.61
3.26
4.68
1.81
4.68
6.97
8.27
8.07
9.95
11.58
13.06
10.7
9.45
11.92
11.72
15.08
15.08
Basic EPS, GAAP
-2.31
-10.81
0.93
4.22
3.32
7.79
8.76
9.53
10.41
8.08
12.84
8.42
9.14
8.85
9.63
9.33
- -
Free Cash Flow per Basic Share
0.01
0.12
0.27
0.37
0.16
0.33
0.23
0.68
0.72
0.94
0.71
1.06
1.12
5.07
5.28
5.34
- -
Dividend per Share
5.87
8.9
12.89
14.26
18.73
25.55
33.5
40.81
50.15
60.87
73.42
83.17
91.64
98.53
105.07
2
2
Book Value per Share
6.21
-5.44
-0.47
- -
3.82
10.13
20.2
22.32
32.73
45.56
59.91
69.6
80.71
88.31
96.8
113.22
113.22
Tangible Book Value per Share
104
104
107
109
109
109
111
112
112
112
112
112
112
112
112
112
112
Basic Weighted Avg Shares
1,161
1,713
2,194
2,145
2,221
2,926
3,287
3,879
4,177
4,416
5,004
5,289
5,404
6,235
6,369
7,458
7,458
Sales/Revenue/Turnover
16.18
34.03
38.44
32.87
37.11
44.72
42.82
38.63
39.44
40.58
41.86
31.87
25.59
27.72
24.79
25.34
25.34
Operating Margin (%)
50
55
74
100
90
87
128
183
211
258
287
350
350
352
366
401
401
Depreciation Expense
167
338
498
197
510
758
915
901
1,111
1,293
1,459
1,196
1,056
1,333
1,311
1,687
1,687
Net Income, GAAP
11.65
28.36
34.2
26.17
30.74
35.06
32.18
32.68
28.44
25.74
28
27.63
26.02
27.08
28.5
25.34
25.34
Effective Tax Rate (%)
14.36
19.71
22.7
9.2
22.95
25.92
27.86
23.22
26.59
29.28
29.16
22.61
19.55
21.38
20.59
22.62
22.62
Profit Margin (%)
184
-280
-82
-406
-266
268
777
1,119
2,169
3,160
4,485
5,399
6,435
7,031
7,831
9,369
9,369
Working Capital
370
1,394
1,167
879
540
388
195
198
70
120
138
265
224
228
209
117
117
LT Debt
645
984
1,657
1,711
2,164
3,359
4,852
5,817
7,048
8,674
10,326
11,404
12,842
13,711
14,687
16,831
16,831
Total Equity
- -
19.24
16.96
15.15
17.08
22.05
19.58
17.02
16.95
16.2
15.38
10.92
8.21
9.19
7.69
8.74
8.74
Return on Invested Capital (%)
- -
19.57
17.53
7.72
17.16
22.42
22.33
18.13
18.7
18.72
17.17
12.12
10.29
11.44
10.64
24.24
24.24
Return on Capital (%)
- -
44.1
43.4
13.49
28.39
31.48
28.22
21.79
21.87
20.86
19.46
13.67
10.81
12.54
11.51
28.17
28.17
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
187
- -
204
LT Borrowings
87
- -
79
LT Finance Leases
72
- -
38
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
112
- -
112
Market Capitalization
36,411
33,699
28,575

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
9,335
- -
10,436
Cash, Cash Equivalents & STI
6,190
- -
7,084
Accounts Receivable, Net
1,253
- -
1,450
Inventories
1,734
- -
1,773
Total Current Liabilities
1,067
- -
1,067
Payables & Accruals
- -
- -
- -
ST Debt
187
- -
204
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.91%
10.31%
14.6%
Free Cash Flow
4.66%
-4.64%
-3.08%
Net Income, GAAP
9.52%
4.7%
28.68%
Sales/Revenue/Turnover
9.96%
8.5%
17.09%
Total Cash Common Dividend
59.65%
82.38%
1.27%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,473
1,578
1,609
1,574
6,235
2025
1,545
1,461
1,691
1,672
6,369
2026
1,859
1,845
1,719
2,034
7,458

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.58
3.08
3.74
- -
11.92
2025
3.05
2.94
3.36
2.37
11.72
2026
3.57
3.87
3.8
3.84
15.08

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
5.07
2025
- -
- -
- -
- -
5.28
2026
- -
- -
- -
- -
5.34
Similar Companies
Stepan Co (SCL)
Avantium N.V. (0RNP.L)
Novonesis (Novozymes) B (NSISBC.XD)
Avantium N.V. (AVTX.AS)
Shida Shinghwa Advanced Material Group Co., Ltd. (603026.SS)
Osaka Organic Chemical Industry Ltd. (4187.T)
Business
Advanced Enzyme Technologies Limited, founded in 1989 and headquartered in Thane, India, researches, develops, manufactures, and markets over 400 proprietary enzymes and probiotics derived from more than 65 indigenous strains; core offerings span human nutrition enzymes used as active pharmaceutical ingredients and in nutraceutical formulations, animal nutrition enzymes enhancing feed digestibility, food processing enzymes for baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, and dairy processing, as well as non-food processing enzymes for textile, leather, paper and pulp, detergents, biofuels, biomass processing, and biocatalysis applications. The company operates nine manufacturing facilities across India, the United States, and other regions, with research and development centers including evoxx technologies GmbH in Germany, serving customers in over 59 countries across six continents in segments such as pharmaceuticals, nutraceuticals, animal healthcare, and industrial bioprocessing. Recent developments include a Rs. 10 million equity investment in its wholly owned subsidiary Advanced Nutrazyme Private Limited in August 2025, a collaboration by 95.72%-owned subsidiary JC Biotech Private Limited with Raywatt Solar Power Systems Private Limited for a captive solar power project at its Andhra Pradesh plant in July 2025, and the incorporation of Advanced Nutrazyme Private Limited as a new wholly owned subsidiary.